Nano-X Imaging (NASDAQ:NNOX) Announces Earnings Results

Nano-X Imaging (NASDAQ:NNOX - Get Free Report) released its earnings results on Monday, April 20th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.35), Zacks reports. The firm had revenue of $3.72 million for the quarter, compared to the consensus estimate of $3.99 million. Nano-X Imaging had a negative return on equity of 64.65% and a negative net margin of 790.87%.During the same period in the prior year, the business earned ($0.21) EPS.

Here are the key takeaways from Nano-X Imaging's conference call:

• Company announced a major U.S. framework with Howard Technology Solutions to deploy 300 Nanox.ARC systems over three years (60 in year one) and cited additional commercial agreements totaling roughly 360–400 systems, which management says underpins its $35M revenue target for 2026.
• Management initiated a manufacturing restructuring that closed the South Korea chip line and recorded a $17.5M non-cash impairment in Q4 2025, shifting production to outsourced partners (including Swiss partner System) to reduce OpEx and cash burn.
• Financial results showed a wider GAAP net loss of $33.4M in Q4 2025 (vs. $14.1M a year ago) and a non‑GAAP net loss of $11.2M, while revenue remained small at $3.7M; the balance sheet held about $60M in cash and marketable securities.
• Progress on regulatory, clinical, and AI fronts — including U.S. TAP2D clearance, updated AMAR approval in Israel, planned MDR submission, a Cedars‑Sinai trial for Nanox.AI, a U.S. IRB lung‑screening trial, and awards at RSNA/ECR — which management says strengthens clinical credibility and adoption potential.
• Management expects most revenue growth in the second half of 2026 but warns deployment timing remains constrained by import licenses, construction and regulatory processes; roughly 38 systems are at various deployment stages and ~15 installs are expected in the next few months, so revenue conversion timing is uncertain.

Nano-X Imaging Trading Up 0.3%

NNOX traded up $0.01 during trading hours on Thursday, hitting $1.72. The company's stock had a trading volume of 1,779,778 shares, compared to its average volume of 1,271,010. Nano-X Imaging has a fifty-two week low of $1.66 and a fifty-two week high of $5.86. The firm has a market capitalization of $112.13 million, a PE ratio of -1.08 and a beta of 1.39. The company has a 50-day simple moving average of $2.37 and a 200 day simple moving average of $2.95.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on NNOX shares. Cantor Fitzgerald raised Nano-X Imaging to a "strong-buy" rating in a research report on Wednesday, March 4th. Zacks Research downgraded shares of Nano-X Imaging from a "hold" rating to a "strong sell" rating in a report on Wednesday, April 22nd. D. Boral Capital reiterated a "buy" rating and set a $5.00 target price on shares of Nano-X Imaging in a research note on Monday, April 20th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Nano-X Imaging in a report on Friday, April 10th. Three investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $5.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Weiss Asset Management LP bought a new stake in shares of Nano-X Imaging during the 4th quarter worth about $8,424,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Nano-X Imaging by 232.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,160,806 shares of the company's stock worth $10,793,000 after acquiring an additional 1,510,806 shares in the last quarter. State Street Corp raised its position in Nano-X Imaging by 1.2% in the fourth quarter. State Street Corp now owns 1,176,202 shares of the company's stock worth $3,293,000 after acquiring an additional 14,422 shares in the last quarter. UBS Group AG lifted its holdings in Nano-X Imaging by 68.8% in the 3rd quarter. UBS Group AG now owns 1,086,645 shares of the company's stock valued at $4,021,000 after acquiring an additional 442,899 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Nano-X Imaging by 4.8% in the 4th quarter. Geode Capital Management LLC now owns 824,594 shares of the company's stock valued at $2,309,000 after acquiring an additional 37,436 shares during the last quarter. Institutional investors own 21.49% of the company's stock.

Nano-X Imaging Company Profile

Nano-X Imaging Ltd. is a medical technology company developing and commercializing a digital X-ray imaging platform designed to lower the cost and increase the accessibility of diagnostic imaging. Its flagship product, the Nanox.ARC, leverages a proprietary micro-electromechanical system (MEMS) based digital X-ray source and advanced image processing software to provide 2D and 3D imaging capabilities on a compact footprint. The system aims to streamline radiology workflows and facilitate point-of-care diagnostics in hospitals, clinics and outpatient settings.

The Nanox.ARC platform integrates a novel cold cathode X-ray source, which enables multiple emission points without the need for rotating anode tubes.